Allianz Asset Management AG continued to hold its stake in Zogenix, Inc. (NASDAQ:ZGNX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,586 shares of the company’s stock at the end of the fourth quarter. Allianz Asset Management AG owned approximately 0.15% of Zogenix worth $457,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of ZGNX. Oppenheimer & Co. Inc. purchased a new position in shares of Zogenix during the third quarter valued at approximately $169,000. Bailard Inc. bought a new position in shares of Zogenix during the third quarter valued at about $1,388,000. Cadian Capital Management LP boosted its position in shares of Zogenix by 30.5% in the third quarter. Cadian Capital Management LP now owns 192,500 shares of the company’s stock valued at $2,200,000 after buying an additional 45,000 shares in the last quarter. Great Point Partners LLC bought a new position in shares of Zogenix during the third quarter valued at about $27,900,000. Finally, RA Capital Management LLC boosted its position in shares of Zogenix by 8.4% in the third quarter. RA Capital Management LLC now owns 2,656,166 shares of the company’s stock valued at $31,451,000 after buying an additional 204,929 shares in the last quarter. 84.32% of the stock is owned by institutional investors and hedge funds.
Shares of Zogenix, Inc. (NASDAQ:ZGNX) traded down 0.234% on Friday, hitting $10.675. 82,722 shares of the stock traded hands. The stock’s market cap is $264.88 million. Zogenix, Inc. has a 52-week low of $7.33 and a 52-week high of $13.70. The stock’s 50 day moving average price is $10.42 and its 200 day moving average price is $10.56.
Several brokerages recently issued reports on ZGNX. Aegis reiterated a “buy” rating and set a $28.00 price target on shares of Zogenix in a research report on Saturday, March 11th. Zacks Investment Research cut shares of Zogenix from a “buy” rating to a “hold” rating in a report on Wednesday, March 15th.
In other news, Director Renee P. Tannenbaum purchased 5,000 shares of the business’s stock in a transaction dated Thursday, March 16th. The stock was acquired at an average price of $11.00 per share, with a total value of $55,000.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $110,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 5.00% of the company’s stock.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.